Renata Solimini*, Maria Concetta Rotolo, Simona Pichini and Roberta Pacifici Pages 527 - 533 ( 7 )
Background & Objective: Medical cannabis is increasingly used as a treatment or adjunct treatment with different levels of efficacy in several neurological disorders or related symptoms (such as multiple sclerosis, autism, Parkinson and Alzheimer disease, Tourette’s syndrome, Huntington’s disease, neuropathic pain, epilepsy, headache), as well as in other medical conditions (e.g. nausea and vomiting, glaucoma, appetite stimulation, cancer, inflammatory conditions, asthma). Nevertheless, a number of neurological adverse effects from use of medical cannabis on the short- and on the longterm have been reported, in addition to other adverse health events.Conclusion: It has been noticed that the use of medical cannabis can lead to a paradoxical effects depending on the amount of delta-9-tetrahydrocannabinol (THC) -like cannabinoids the preparation contain. Accordingly, some neurological disorders or symptoms (e.g. multiple sclerosis, seizures, epilepsy, headache) may be caused or exacerbated by the same treatment supposed to cure them. The current review presents an update of the neurological adverse effects resulting from the use of cannabis for medical purposes, highlighting the need to weigh the benefits and risks, when using cannabinoidbased treatments.
Adverse effects, antipsychotic, compounds, medical cannabis, neurological disorders, Parkinson.
National Centre on Addiction and Doping, Istituto Superiore di Sanità, viale Regina Elena 299, 00161, Roma, National Centre on Addiction and Doping, Istituto Superiore di Sanità, Roma, National Centre on Addiction and Doping, Istituto Superiore di Sanità, Roma, National Centre on Addiction and Doping, Istituto Superiore di Sanità, Roma